These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 24507111

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.
    Shin K, Kim KH, Yoon MS, Suh DS, Lee JY, Kim A, Eo W.
    Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.
    Kreuzinger C, Gamperl M, Wolf A, Heinze G, Geroldinger A, Lambrechts D, Boeckx B, Smeets D, Horvat R, Aust S, Hamilton G, Zeillinger R, Cacsire Castillo-Tong D.
    Cancer Lett; 2015 Jul 01; 362(2):218-28. PubMed ID: 25862976
    [Abstract] [Full Text] [Related]

  • 7. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
    Schrader KA, Hurlburt J, Kalloger SE, Hansford S, Young S, Huntsman DG, Gilks CB, McAlpine JN.
    Obstet Gynecol; 2012 Aug 01; 120(2 Pt 1):235-40. PubMed ID: 22776961
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.
    Hyman DM, Long KC, Tanner EJ, Grisham RN, Arnold AG, Bhatia J, Phillips MF, Spriggs DR, Soslow RA, Kauff ND, Levine DA.
    Gynecol Oncol; 2012 Aug 01; 126(2):224-8. PubMed ID: 22579790
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ovarian cancer genome sequencing unveils findings.
    Brower V.
    J Natl Cancer Inst; 2011 Sep 07; 103(17):1288-90. PubMed ID: 21852263
    [No Abstract] [Full Text] [Related]

  • 16. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
    Leonhardt K, Einenkel J, Sohr S, Engeland K, Horn LC.
    Int J Gynecol Pathol; 2011 Sep 07; 30(5):417-24. PubMed ID: 21804388
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
    Wen J, Shi JL, Shen DH, Chen YX, Song QJ.
    Zhonghua Bing Li Xue Za Zhi; 2012 Jul 07; 41(7):433-7. PubMed ID: 22932451
    [Abstract] [Full Text] [Related]

  • 20. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.
    Vartiainen J, Lassus H, Lehtovirta P, Finne P, Alfthan H, Butzow R, Stenman UH.
    Int J Cancer; 2008 May 01; 122(9):2125-9. PubMed ID: 18098286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.